RESUMEN
BACKGROUND: There are calls worldwide for the mainstreaming of genetic testing in breast cancer (BC) clinics, but health care professionals (HCPs) are not always familiar with nor confident about genetic counselling. TRUSTING (Talking about Risk & uncertainties of Testing in Genetics is an educational programme shown to significantly improve HCPs' knowledge, communication, self-confidence, and self-awareness. We rolled out TRUSTING workshops across the UK and probed their influence on mainstreaming within BC clinics. METHODS: 1 surgeon, 3 oncologists, and 1 nurse specialist who had attended the original TRUSTING evaluation project were trained to facilitate the 8-hour programme in pairs. The participants (all health care professionals) attending their workshops completed 3 questionnaires: - 1) the Intolerance to Uncertainty Scale, 2) an 18-item multiple choice knowledge questionnaire about BRCA 1/2 gene testing, incidence and risk reducing interventions and 3) a 10-item questionnaire exploring self-confidence when advising patients and their families about these issues. Both knowledge and self-confidence were re-tested post workshop together with evaluation of the facilitators' approach and overall satisfaction with the event. Follow-up questionnaires 3-12 months later examined impact of workshops on HCPs' own practice and how mainstreaming was working in their clinics. RESULTS: 120 HCPs (61 surgeons; 41 nurses; 9 oncologists; 9 other) attended 12 workshops. Knowledge scores (mean change = 6.58; 95% CI 6.00 to 7.17; p<0.001), and self-confidence (mean change = 2.64; 95% CI 2.33 to 2.95; p<0.001) improved significantly post workshop. Ratings for the facilitators' approach were uniformly high (mean range 9.6 to 9.9 /10). Most delegates found the workshops useful, enjoyable, and informative and 98% would definitively recommend them to colleagues. Follow-up data (n = 72/96) showed that 57% believed attendance had improved their own practice when discussing genetic testing with their patients. When asked about mainstreaming more generally, 78% reported it was working well, 18% had not yet started, and 3% thought it was problematic in their centre. CONCLUSIONS: Discussing the implications that having a pathogenic gene alteration has for patients' treatment and risk-reducing interventions is complex when patients are already coming to terms with a breast cancer diagnosis. Training facilitators enhanced the wider roll-out of the TRUSTING educational programme and is an effective means of helping HCPs now involved in the mainstreaming of genetic testing.
Asunto(s)
Neoplasias de la Mama , Asesoramiento Genético , Pruebas Genéticas , Personal de Salud , Humanos , Neoplasias de la Mama/genética , Neoplasias de la Mama/prevención & control , Femenino , Personal de Salud/psicología , Personal de Salud/educación , Encuestas y Cuestionarios , Conocimientos, Actitudes y Práctica en Salud , Adulto , Persona de Mediana Edad , Proteína BRCA2/genética , Reino Unido , Masculino , Autoimagen , Proteína BRCA1/genéticaRESUMEN
BACKGROUND: People with cancer are at increased risk of hospitalisation and death following infection with SARS-CoV-2. Therefore, we aimed to conduct one of the first evaluations of vaccine effectiveness against breakthrough SARS-CoV-2 infections in patients with cancer at a population level. METHODS: In this population-based test-negative case-control study of the UK Coronavirus Cancer Evaluation Project (UKCCEP), we extracted data from the UKCCEP registry on all SARS-CoV-2 PCR test results (from the Second Generation Surveillance System), vaccination records (from the National Immunisation Management Service), patient demographics, and cancer records from England, UK, from Dec 8, 2020, to Oct 15, 2021. Adults (aged ≥18 years) with cancer in the UKCCEP registry were identified via Public Health England's Rapid Cancer Registration Dataset between Jan 1, 2018, and April 30, 2021, and comprised the cancer cohort. We constructed a control population cohort from adults with PCR tests in the UKCCEP registry who were not contained within the Rapid Cancer Registration Dataset. The coprimary endpoints were overall vaccine effectiveness against breakthrough infections after the second dose (positive PCR COVID-19 test) and vaccine effectiveness against breakthrough infections at 3-6 months after the second dose in the cancer cohort and control population. FINDINGS: The cancer cohort comprised 377 194 individuals, of whom 42 882 had breakthrough SARS-CoV-2 infections. The control population consisted of 28 010 955 individuals, of whom 5 748 708 had SARS-CoV-2 breakthrough infections. Overall vaccine effectiveness was 69·8% (95% CI 69·8-69·9) in the control population and 65·5% (65·1-65·9) in the cancer cohort. Vaccine effectiveness at 3-6 months was lower in the cancer cohort (47·0%, 46·3-47·6) than in the control population (61·4%, 61·4-61·5). INTERPRETATION: COVID-19 vaccination is effective for individuals with cancer, conferring varying levels of protection against breakthrough infections. However, vaccine effectiveness is lower in patients with cancer than in the general population. COVID-19 vaccination for patients with cancer should be used in conjunction with non-pharmacological strategies and community-based antiviral treatment programmes to reduce the risk that COVID-19 poses to patients with cancer. FUNDING: University of Oxford, University of Southampton, University of Birmingham, Department of Health and Social Care, and Blood Cancer UK.
Asunto(s)
COVID-19 , Neoplasias , Vacunas Virales , Adolescente , Adulto , COVID-19/epidemiología , COVID-19/prevención & control , Vacunas contra la COVID-19 , Estudios de Casos y Controles , Humanos , Neoplasias/epidemiología , SARS-CoV-2 , Eficacia de las VacunasRESUMEN
The deeply embedded inequalities in gender which mark most contemporary societies have led to a world shaped by male perspectives. This world fails to accommodate adequately the needs and experiences of women: no more evident than in the transport sector, where a 'default male' perspective dominates the planning and policies that shape our roads, railways, airlines, and shipping. This paper argues that the ways in which masculinity infuses transport systems mean they are integral to debates on gender and work. They impact both the way women experience travel and their access to places of work. A multi-transport domain scoping study has been conducted to review the literature for key gender factors that influence the use of road, rail, aviation, and maritime transport modes. A multi-disciplinary approach is proposed which incorporates perspectives and methods from the social sciences that can help to foster Gender-Equitable Human Factors (GE-HF).Practitioner summary: This paper seeks to identify the gender issues related to transport and work. A scoping review provides key factors that detail how women are disadvantaged by current transport systems. It presents gaps in knowledge that future research needs to fill. Women must be included in key decisions within the transport sector.
Asunto(s)
Aviación , Transportes , Masculino , Humanos , Femenino , Viaje , NavíosRESUMEN
AIM: The aim of this work was to examine the burden of further treatments in patients with colorectal cancer following a decision about lung metastasectomy. METHOD: Five teams participating in the Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) study provided details on subsequent local treatments for lung metastases, including the use of chemotherapy. For patients in three groups (no metastasectomy, one metastasectomy or multiple local interventions), baseline factors and selection criteria for additional treatments were examined. RESULTS: The five teams recruited 220 patients between October 2010 and January 2017. No lung metastasectomy was performed in 51 patients, 114 patients had one metastasectomy and 55 patients had multiple local interventions. Selection for initial metastasectomy was associated with nonelevated carcinoembryonic antigen, fewer metastases and no prior liver metastasectomy. These patients also had better Eastern Cooperative Oncology Group scores and lung function at baseline. Four sites provided information on chemotherapy in 139 patients: 79 (57%) had one to five courses of chemotherapy, to a total of 179 courses. The patterns of survival after one or multiple metastasectomy interventions showed evidence of guarantee-time bias contributing to an impression of benefit over no metastasectomy. After repeated metastasectomy, a significantly higher risk of death was observed, with no apparent reduction in chemotherapy usage. CONCLUSION: Repeated metastasectomy is associated with a higher risk of death without reducing the use of chemotherapy. Continued monitoring without surgery might reassure patients with indolent disease or allow response assessment during systemic treatment. Overall, the carefully collected information from the PulMICC study provides no indication of an important survival benefit from metastasectomy.
Asunto(s)
Neoplasias Colorrectales , Neoplasias Pulmonares , Metastasectomía , Estudios de Cohortes , Neoplasias Colorrectales/terapia , Humanos , Neoplasias Pulmonares/terapia , Pronóstico , Tasa de SupervivenciaRESUMEN
AIM: We wanted to examine survival in patients with resected colorectal cancer (CRC) whose lung metastases are or are not resected. METHODS: Teams participating in the study of Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) identified potential candidates for lung metastasectomy and invited their consent to join Stage 1. Baseline data related to CRC and fitness for surgery were collected. Eligible patients were invited to consent for randomization in the PulMiCC randomized controlled trial (Stage 2). Sites were provided with case report forms for non-randomized patients to record adverse events and death at any time. They were all reviewed at 1 year. Baseline and survival data were analysed for the full cohort. RESULTS: Twenty-five clinical sites recruited 512 patients from October 2010 to January 2017. Data collection closed in October 2020. Before analysis, 28 patients with non-CRC lung lesions were excluded and three had withdrawn consent leaving 481. The date of death was known for 292 patients, 136 were alive in 2020 and 53 at earlier time points. Baseline factors and 5-year survival were analysed in three strata: 128 non-randomized patients did not have metastasectomy; 263 had elective metastasectomy; 90 were from the randomized trial. The proportions of solitary metastases for electively operated and non-operated patients were 69% and 35%. Their respective 5-year survivals were 47% and 22%. CONCLUSION: Survival without metastasectomy was greater than widely presumed. Difference in survival appeared to be largely related to selection. No inference can be drawn about the effect of metastasectomy on survival in this observational study.
Asunto(s)
Neoplasias Colorrectales , Neoplasias Pulmonares , Metastasectomía , Estudios de Cohortes , Humanos , Neoplasias Pulmonares/cirugía , Factores de RiesgoAsunto(s)
Neoplasias Colorrectales/patología , Neoplasias Pulmonares/secundario , Neoplasias Pulmonares/cirugía , Metastasectomía/métodos , Neumonectomía/métodos , Neoplasias Colorrectales/mortalidad , Estudios de Seguimiento , Humanos , Neoplasias Pulmonares/mortalidad , Método Simple Ciego , Análisis de Supervivencia , Resultado del TratamientoRESUMEN
Junior doctors describe a need for greater support and training in end of life care (EoLC) communication skills. The Second Conversation project was designed by a multi-professional steering group as a workplace based training intervention for junior doctors to improve their skills and confidence in undertaking EoLC conversations. Qualitative interviews were carried out with 11 junior doctors and five senior doctors across two sites who took part in, or facilitated, a 'second conversation'. This is a three-step training intervention that involves 1) observation - the junior doctor observes an EoLC conversation between a senior doctor and patient/caregiver; 2) direct experience - the junior doctor undertakes a follow-up second conversation with the patient/caregiver; and 3) reflection - the junior doctor discusses and reflects on the experience with a senior colleague. Interviews were analysed using framework analysis and findings informed iterative changes to the intervention and its implementation using 'Plan, Do, Study, Act' cycles. Benefits that were identified included the flexibility of the intervention and its positive impact on the confidence and skills of junior doctors. The Second Conversation was felt to be of most value to newly qualified doctors and worked well on wards where length of stay was longer and EoLC conversations frequently happen. Further evaluation and exploration of patient and caregiver experiences is required.
RESUMEN
BACKGROUND: Platinum-based combination chemotherapy is standard treatment for the majority of patients with advanced non-small-cell lung cancer (NSCLC). The trial investigates the importance of the choice of platinum agent and dose of cisplatin in relation to patient outcomes. METHODS: The three-arm randomised phase III trial assigned patients with chemo-naïve stage IIIB/IV NSCLC in a 1:1:1 ratio to receive gemcitabine 1250 mg/m2 on days 1 and 8 of a 3-week cycle with cisplatin 80 mg/m2 (GC80) or cisplatin 50 mg/m2 (GC50) or carboplatin AUC6 (GCb6) for a maximum of four cycles. Primary outcome measure was survival time, aiming to test for a difference between treatment arms and also assess non-inferiority with pre-defined margin selected as hazard ratio (HR) of 1.2. Secondary outcome measures included response rate, adverse events and quality of life (QoL). FINDINGS: The trial recruited 1363 patients. Survival time differed significantly across the three treatment arms (p = 0.046) with GC50 worst with median 8.2 months compared to 9.5 for GC80 and 10.0 for GCb6. HRs (adjusted) for GC50 compared to GC80 was 1.13 (95% confidence interval [CI] 0.99-1.29) and for GC50 compared to GCb6 was 1.23 (95% CI: 1.08-1.41). GCb6 was significantly non-inferior to GC80 (HR = 0.93, upper limit of one-sided 95% CI 1.04). Adjusting for QoL did not change the findings. Best objective response rates were 29% (GC80), 20% (GC50) and 27% (GCb6), p < 0.007. There were more dose reductions and treatment delays in the GCb6 arm and more adverse events (60% with at least one grade 3-4 compared to 43% GC80 and 30% GC50). INTERPRETATION: In combination with gemcitabine, carboplatin at AUC6 is not inferior to cisplatin at 80 mg/m2 in terms of survival. Carboplatin was associated with more adverse events and not with better quality of life. Cisplatin at the lower dose of 50 mg/m2 has worse survival which is not compensated by better quality of life. CLINICALTRIALS. GOV IDENTIFIER: NCT00112710. EUDRACT NUMBER: 2004-003868-30. CANCER RESEARCH UK TRIAL IDENTIFIER: CRUK/04/009.
Asunto(s)
Antineoplásicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Neoplasias Pulmonares/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Carboplatino/administración & dosificación , Carcinoma de Pulmón de Células no Pequeñas/patología , Cisplatino/administración & dosificación , Desoxicitidina/administración & dosificación , Desoxicitidina/análogos & derivados , Femenino , Humanos , Neoplasias Pulmonares/patología , Masculino , Persona de Mediana Edad , Modelos de Riesgos Proporcionales , Calidad de Vida , Análisis de Supervivencia , GemcitabinaRESUMEN
Effective communication between clinicians and their patients has a positive impact not only on clinical outcomes but also on their experience of care. Communication skills are a core clinical skill, which can be taught by a number of methods. Understanding the impact of one's own communication skills has on a patient and their family can help hone a clinician's skills to improve both patient and clinician satisfaction.
Asunto(s)
Comunicación , Personal de Salud/educación , Relaciones Médico-Paciente , Manejo de la Enfermedad , HumanosRESUMEN
The recent economic recession has impacted substantially on the graduate labour market, with many graduates now struggling to find secure employment in professional careers. In this context, temporary, unpaid 'internships' have emerged as increasingly important as a 'way in' to work for this group. Yet while there has been much media and policy debate on internships, academic consideration has been scant. This article begins to address this knowledge gap by drawing on a study of interns in a third sector environmental organisation. The research findings reveal that unpaid internships were rationalised through a complex mix of political motivations, career ambitions and lifestyle aims, but these intersected in important ways with social class. These findings are not only of empirical interest, contributing to our knowledge of graduate negotiations of precarity, but also of theoretical value, extending our understanding of young people's agency and motivations in transitions into work.
RESUMEN
A 30-year-old lady treated with capecitabine for primary colon adenocarcinoma developed liver lesions suspicious for metastasis. Liver biopsies showed sinusoidal dilatation thought to be secondary to capecitabine. This case highlights the importance of differentiating between benign and malignant liver lesions during cancer surveillance preventing unnecessary liver resections for benign disease.
RESUMEN
Diarrhoea induced by chemotherapy in cancer patients is common, causes notable morbidity and mortality, and is managed inconsistently. Previous management guidelines were based on poor evidence and neglect physiological causes of chemotherapy-induced diarrhoea. In the absence of level 1 evidence from randomised controlled trials, we developed practical guidance for clinicians based on a literature review by a multidisciplinary team of clinical oncologists, dietitians, gastroenterologists, medical oncologists, nurses, pharmacist, and a surgeon. Education of patients and their carers about the risks associated with, and management of, chemotherapy-induced diarrhoea is the foundation for optimum treatment of toxic effects. Adequate--and, if necessary, repeated--assessment, appropriate use of loperamide, and knowledge of fluid resuscitation requirements of affected patients is the second crucial step. Use of octreotide and seeking specialist advice early for patients who do not respond to treatment will reduce morbidity and mortality. In view of the burden of chemotherapy-induced diarrhoea, appropriate multidisciplinary research to assess meaningful endpoints is urgently required.
Asunto(s)
Antidiarreicos/uso terapéutico , Antineoplásicos/efectos adversos , Diarrea/inducido químicamente , Diarrea/terapia , Fluidoterapia/métodos , Neoplasias/tratamiento farmacológico , Antineoplásicos/uso terapéutico , Terapia Combinada , Diarrea/mortalidad , Femenino , Humanos , Masculino , Guías de Práctica Clínica como Asunto , Medición de Riesgo , Índice de Severidad de la Enfermedad , Tasa de Supervivencia , Resultado del TratamientoAsunto(s)
Neoplasias Colorrectales/mortalidad , Neoplasias Colorrectales/cirugía , Neoplasias Pulmonares/secundario , Neoplasias Pulmonares/cirugía , Metastasectomía , Neumonectomía , Neoplasias Colorrectales/patología , Humanos , Neoplasias Pulmonares/mortalidad , Calidad de Vida , Tasa de Supervivencia , Resultado del TratamientoAsunto(s)
Neoplasias Encefálicas/diagnóstico , Neoplasias Encefálicas/secundario , Continuidad de la Atención al Paciente , Servicio de Urgencia en Hospital/estadística & datos numéricos , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/patología , Sistemas de Registros Médicos Computarizados , Adulto , Humanos , Imagen por Resonancia Magnética , Masculino , Reino UnidoRESUMEN
PROBLEM: The need to develop a patient pathway for emergency admissions who have a previously undiagnosed cancer. DESIGN: The existing patient pathway was audited and process-mapped to identify delays and areas for improvement. Discussions with key stakeholders were held to identify their needs from an acute oncology service. STRATEGIES FOR CHANGE: A new patient pathway was developed, and a new online referral process was implemented. The publicity and education campaign was repeatedly aimed at referring physicians at consultant and junior level, and took the form of emails and presentations with handouts at all teaching sessions, multidisciplinary team meetings, the Consultants Committee and Junior Doctors' induction. Effects of change The new system was piloted for 6 months. 12/18 patients were referred via the new pathway. 15/18 patients were referred via the new online system. Length of stay, endoscopies, biopsies and blood tests were all statistically significantly reduced during the study period compared with the original audit. LESSONS LEARNT: The challenge was to convince the referring general physicians to use the new patient pathway and referral method. Incorporating their ideas for improvement and implementation made it more likely that they would take up the new ideas. Education and publicity were also extensive, often repeated, and at both junior and senior level. Having the Lead Cancer Clinician and Acute Medicine Consultant engage directly with consultant colleagues, as well as strong support from the Medical Director, was also crucial to the project's success.
Asunto(s)
Vías Clínicas/organización & administración , Servicio de Urgencia en Hospital/organización & administración , Servicio de Urgencia en Hospital/estadística & datos numéricos , Tiempo de Internación/estadística & datos numéricos , Neoplasias/terapia , Enfermedad Aguda , Técnicas y Procedimientos Diagnósticos , Humanos , Alta del Paciente , Mejoramiento de la Calidad/organización & administración , Derivación y Consulta/organización & administraciónRESUMEN
PURPOSE: Both gemcitabine (GEM) and fluoropyrimidines are valuable treatment for advanced pancreatic cancer. This open-label study was designed to compare the overall survival (OS) of patients randomly assigned to GEM alone or GEM plus capecitabine (GEM-CAP). PATIENTS AND METHODS: Patients with previously untreated histologically or cytologically proven locally advanced or metastatic carcinoma of the pancreas with a performance status Asunto(s)
Adenocarcinoma/tratamiento farmacológico
, Adenocarcinoma/mortalidad
, Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación
, Neoplasias Pancreáticas/tratamiento farmacológico
, Neoplasias Pancreáticas/mortalidad
, Adenocarcinoma/patología
, Adulto
, Anciano
, Anciano de 80 o más Años
, Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos
, Capecitabina
, Intervalos de Confianza
, Desoxicitidina/administración & dosificación
, Desoxicitidina/efectos adversos
, Desoxicitidina/análogos & derivados
, Supervivencia sin Enfermedad
, Relación Dosis-Respuesta a Droga
, Esquema de Medicación
, Femenino
, Fluorouracilo/administración & dosificación
, Fluorouracilo/efectos adversos
, Fluorouracilo/análogos & derivados
, Estudios de Seguimiento
, Humanos
, Infusiones Intravenosas
, Estimación de Kaplan-Meier
, Masculino
, Dosis Máxima Tolerada
, Persona de Mediana Edad
, Invasividad Neoplásica/patología
, Estadificación de Neoplasias
, Neoplasias Pancreáticas/patología
, Probabilidad
, Modelos de Riesgos Proporcionales
, Calidad de Vida
, Medición de Riesgo
, Estadísticas no Paramétricas
, Análisis de Supervivencia
, Factores de Tiempo
, Resultado del Tratamiento
, Reino Unido
, Gemcitabina